MarketsSudeep Pharma IPO Sees Strong Day 2 Bidding; Here's What Brokerages SayBY Outlook Business Desk
CorporateUS Pharma Firm Eli Lilly Partners with Cipla to Sell Weight-loss Drug in India under Brand Name ‘Yurpeak’BY Outlook Business Desk
CorporateWelcure Board Considers Telexcell Offer for Up to 25% Stake; Rejects Demand for ControlBY PTI
Economy & PolicyAmid Air of Uncertainty with Tariffs, Indian Pharma Firms May Look at More Third-party ManufacturingBY Outlook Business Desk
NewsTrump Targets Pharma Ads — New Rules for TV, Social Media & Telehealth: Here’s What Led to ItBY Outlook Business Desk
CorporateAmansa Investments Pumps ₹250 Cr in Rubicon Research in Pre-IPO Funding Round; Issue by Year-EndBY PTI
MarketsGlenmark Pharma Shares Surge 10% On Arm’s Landmark Deal with AbbVie For Cancer DrugBY Outlook Business Desk
MarketsSun Pharma Advanced Research Tumbles Over 18%: Here’s What Spooked InvestorsBY Outlook Business Desk
MagazineCorporate Strategist: After Winning India with Price, Mankind Pharma Chases Global Growth with PremiumBY Yuthika Bhargava
MarketsNew Product Launches Save the Day for Dr Reddy’s in Q4, But Margins Remain a Sour PillBY Harshita Dudeja
MarketsCipla, Lupin, Aurobindo Shares Drop as Trump’s Push to Boost US Drug Mfg Sours SentimentBY Outlook Business Desk
MarketsAs Trump’s April 2 Tariff Call Nears, These Indian Sectors Could be in TroubleBY Harshita Dudeja
